Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kelly M. Ramsbottom"'
Autor:
Tanja Fauti, Lisa Wellinger, Joseph A. Trapani, Axel Paehler, Daniela Geiss, Kelly M Ramsbottom, Laura Jarassier, Phillip Thienger, Leonie A. Cluse, Conor J. Kearney, Thomas Friess, Stephin J. Vervoort, Jane Oliaro, Daniel Rohle, Ricky W. Johnstone, Marina Bacac, Simon J. Hogg, Astrid Ruefli-Brasse, Dane M. Newman, Daniel Marbach, Jake Shortt, Jessica Michie
Publikováno v:
Cancer Immunology Research. 10:87-107
Targeting chromatin binding proteins and modifying enzymes can concomitantly affect tumor cell proliferation and survival, as well as enhance antitumor immunity and augment cancer immunotherapies. By screening a small-molecule library of epigenetics-
Autor:
Emily J. Lelliott, Kelly M. Ramsbottom, Mark R. Dowling, Carolyn Shembrey, Tahereh Noori, Conor J. Kearney, Jessica Michie, Ian A. Parish, Margaret A. Jordan, Alan G. Baxter, Neil D. Young, Amelia J. Brennan, Jane Oliaro
Publikováno v:
Frontiers in Immunology. 13
Cytotoxic lymphocytes are essential for anti-tumor immunity, and for effective responses to cancer immunotherapy. Natural killer cell granule protein 7 (NKG7) is expressed at high levels in cytotoxic lymphocytes infiltrating tumors from patients trea
Autor:
Matteo Costacurta, Edwin D. Hawkins, Ricky W. Johnstone, Grant A. McArthur, Jane Oliaro, Paul J Neeson, Paul A. Beavis, Stephin J. Vervoort, Joe Jiang Zhu, Deborah Meyran, Conor J. Kearney, Emily J. Lelliott, Ian A. Parish, Pilar M. Dominguez, Laura Kirby, Nicole M. Haynes, Lydia Lim, Luciano G. Martelotto, Kelly M Ramsbottom, Magnus Zethoven, Isabella Y. Kong, Karen E. Sheppard, Jarrod J. Sandow, Izabela Todorovski
Publikováno v:
Cancer Discovery. 11:2582-2601
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical s
Autor:
Kelly M Ramsbottom, Conor J. Kearney, Stephin J. Vervoort, Lizzy Pijpers, Jessica Michie, Jane Oliaro, Ricky W. Johnstone, Madison J. Kelly, Andrew J. Freeman
Publikováno v:
Cell Reports, Vol 28, Iss 11, Pp 2784-2794.e5 (2019)
Summary: Despite the clinical success of cancer immunotherapies, the majority of patients fail to respond or develop resistance through disruption of pathways that promote neo-antigen presentation on MHC I molecules. Here, we conducted a series of un
Autor:
Mayura V, Wagle, Stephin J, Vervoort, Madison J, Kelly, Willem, Van Der Byl, Timothy J, Peters, Ben P, Martin, Luciano G, Martelotto, Simone, Nüssing, Kelly M, Ramsbottom, James R, Torpy, Deborah, Knight, Sinead, Reading, Kevin, Thia, Lisa A, Miosge, Debbie R, Howard, Renee, Gloury, Sarah S, Gabriel, Daniel T, Utzschneider, Jane, Oliaro, Jonathan D, Powell, Fabio, Luciani, Joseph A, Trapani, Ricky W, Johnstone, Axel, Kallies, Christopher C, Goodnow, Ian A, Parish
Publikováno v:
Nature communications. 12(1)
Chronic stimulation of CD8
Autor:
Grant A. McArthur, Riyaben P. Patel, Carleen Cullinane, Claire Martin, Anthony T. Papenfuss, Amanda J Oliver, Kelly M Ramsbottom, Emily J. Lelliott, Nicole M. Haynes, Stefano Mangiola, Peter Lau, Lydia Lim, Jane Oliaro, Laura Kirby, Karen E. Sheppard, Magnus Zethoven, Luciano G. Martelotto, Alison Slater
Publikováno v:
Cancer immunology research. 9(2)
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAFV600 mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combination on an
Autor:
Conor J. Kearney, John Silke, Kelly M Ramsbottom, Andrew J. Freeman, Jane Oliaro, Najoua Lalaoui
Publikováno v:
Cell Death & Differentiation. 24:1705-1716
Smac-mimetics are emerging as promising anti-cancer agents and are being evaluated in clinical trials for a variety of malignancies. Smac-mimetics can induce TNF production from a subset of tumor cells and simultaneously sensitize them to TNF-induced
Autor:
Laura Kirby, Shatha AbuHammad, Richard J. Young, Peter Lau, Grant A. McArthur, Claire Martin, Katrina Meeth, Karen E. Sheppard, Jessica Michie, Kelly M Ramsbottom, Nicole M. Haynes, Rachael Walker, Fernando Souza-Fonseca-Guimaraes, Jane Oliaro, Emily J. Lelliott, Carleen Cullinane, Alison Slater
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor response rates to the individual therapies has limited their success. Designing rational combinations of targeted therap
Autor:
Min Gu, Heather J. Melichar, Stephen B. Ting, David J. Izon, Edwin D. Hawkins, Carmen Molina-París, Raz Shimoni, Mandy J. Ludford-Menting, Patrick O. Humbert, Sarah M. Russell, Grant Lythe, Joseph Reynolds, Kim Pham, Kelly M Ramsbottom, Jane Oliaro, Mirren Charnley, Ellen A. Robey
Publikováno v:
The Journal of Cell Biology
T cell precursors undergo asymmetric cell division after T cell receptor genomic recombination, with stromal cell cues controlling the differential inheritance of fate determinants Numb and α-Adaptin by the daughters of a dividing DN3a T cell precur
Autor:
Kelly M Ramsbottom, Ilia Voskoboinik, Najoua Lalaoui, Conor J. Kearney, Paul A. Beavis, Jane Oliaro, Ricky W. Johnstone, Andrew J. Freeman, Robert G. Ramsay, Emily J. Lelliott, Jessica Michie, John Silke, Vignesh Narasimhan, Phillip K. Darcy, Stephin J. Vervoort
Publikováno v:
Cancer immunology research. 7(2)
Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B-cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poor, likely d